AVEO Oncology (also known as AVEO Pharmaceuticals, Inc.)
30 Winter Street
Boston
Massachusetts
02108
United States
457 articles about AVEO Oncology (also known as AVEO Pharmaceuticals, Inc.)
-
AVEO Oncology to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 10, 2021
5/3/2021
AVEO Oncology to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 10, 2021
-
AVEO Announces Appointment of Kevin Cullen, M.D., to Its Board of Directors
4/16/2021
AVEO Oncology, a commercial and clinical development stage biopharmaceutical company, announced the appointment of Kevin J. Cullen, M.D., to the Company’s Board of Directors.
-
AVEO Oncology Announces Addition of FOTIVDA® (tivozanib) into National Comprehensive Cancer Network Clinical Practice Guidelines
3/29/2021
AVEO Oncology Announces Addition of FOTIVDA ® (tivozanib) into National Comprehensive Cancer Network Clinical Practice Guidelines
-
FDA Action Alert: Merck, Aveo and Acadia
3/29/2021
As this week’s FDA Action Alert emphasizes, not everything goes as planned with the U.S. FDA. With three PDUFA dates, two of them ran into issues. Read on to find out more. -
AVEO Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares
3/26/2021
AVEO Oncology (Nasdaq: AVEO) today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of its common stock, which includes the full exercise by the underwriters of their option to purchase an additional 900,000 shares, at a price to the public of $8.00 per share.
-
AVEO Announces Pricing of $48.0 Million Public Offering of Common Stock - Mar 24, 2021
3/24/2021
AVEO Oncology announced that it has priced its previously announced underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $8.00 per share.
-
AVEO Oncology Announces U.S. Commercial Availability of FOTIVDA® (tivozanib) for the Treatment of Adult Patients With Relapsed or Refractory Advanced Renal Cell Carcinoma Ahead of Previous Guidance
3/22/2021
FOTIVDA is the First Therapy Approved for Adults with Relapsed or Refractory Advanced RCC Following Two or More Prior Systemic Therapies
-
AVEO Announces Proposed Public Offering of Common Stock - Mar 22, 2021
3/22/2021
AVEO Oncology announced that it has commenced an underwritten public offering of 5,000,000 shares of its common stock.
-
AVEO Oncology Reports Full Year 2020 Financial Results and Provides Business Update
3/16/2021
AVEO Oncology Reports Full Year 2020 Financial Results and Provides Business Update – FOTIVDA ® (tivozanib) Approved for Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma Following Two or More Prior Systemic Therapies; AVEO Plans to Make FOTIVDA Available to Patients in the U.S. by March 31, 2021 –
-
AVEO Oncology to Regain Ex-North American Rights to AV-203
3/15/2021
AVEO Oncology to Regain Ex-North American Rights to AV-203 - AVEO Pipeline to Include Global Rights to Three Clinical-Stage and One Commercial-Stage Assets, Including Ficlatuzumab and AV-380 -
-
Clinical Catch-Up: March 8-12
3/15/2021
It was another busy week for clinical trial announcements. Here’s a look including trials for COVID-19, migraine, Parkinson's disease, Alzheimer's, HIV and more. -
Nearly five years to the day after striking the deal, AVEO Oncology and CANbridge Life Sciences announce the termination of their collaboration and licensing agreement for AVEO’s AV-203.
-
AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) in Pivotal Phase 3 TiNivo-2 Trial in IO Relapsed Renal Cell Carcinoma
3/12/2021
AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate FOTIVDA ® (tivozanib) in Combination with OPDIVO ® (nivolumab) in Pivotal Phase 3 TiNivo-2 Trial in IO Relapsed Renal Cell Carcinoma
-
Today, AVEO Oncology announced it had inked a clinical trial collaboration and supply deal with Bristol Myers Squibb to study Fotivda in combination with BMS’s checkpoint inhibitor Opdivo in advanced r/r RCC after previous immunotherapy exposure.
-
AVEO Oncology Announces Drawdown of $20 Million Tranche Under Hercules Debt Facility
3/11/2021
AVEO Oncology (Nasdaq: AVEO) today announced that it has completed a drawdown of $20 million under its previously announced $45 million loan and security agreement with Hercules Capital, Inc. (NYSE: HTGC, “Hercules”) and its affiliates.
-
The U.S. FDA approved AVEO Oncology’s Fotivda (tivozanib) for adults with relapsed or refractory advanced renal cell carcinoma (RCC) in people who have had two or more previous systemic therapies.
-
AVEO Announces Appointment of Mike Ferraresso to Chief Commercial Officer
3/10/2021
AVEO Oncology (Nasdaq:AVEO) today announced the appointment of Mike Ferraresso to chief commercial officer. Mr. Ferraresso will be responsible for managing AVEO’s commercial strategy and operations, including the commercialization of FOTIVDA® (tivozanib
-
AVEO Oncology Announces U.S. FDA Approval of FOTIVDA® (tivozanib) for the Treatment of Adult Patients with Relapsed or Refractory Advanced Renal Cell Carcinoma
3/10/2021
AVEO Oncology (Nasdaq: AVEO) today announced that the U.S. Food and Drug Administration (FDA) has approved FOTIVDA® (tivozanib) for the treatment of adults with relapsed or refractory advanced renal cell carcinoma (RCC) who have received two or more prior systemic therapies. FOTIVDA is an oral, next-generation vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI).
-
AVEO Oncology to Present at the H.C. Wainwright Global Life Sciences Conference - Mar 02, 2021
3/2/2021
AVEO Oncology announced that Michael Bailey, president and chief executive officer of AVEO, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually on March 9-10, 2021.
-
AVEO Oncology Announces Participation at the 2021 SVB Leerink Global Healthcare Conference
2/18/2021
AVEO Oncology announced that Michael Bailey, president and chief executive officer of AVEO, will participate in a fireside chat at the 2021 SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 3:00 p.m. Eastern Time.